Companies › SecuraBio
1 active drug program in 13 registered trials: 7 Phase 1, 5 Phase 2, 1 Phase 3; Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Duvelisib PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor | PIK3CD, PIK3CG | Phase 3 | Lymphoma; Newly Diagnosed Peripheral T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Recurrent Chronic Lymphocytic Leukemia … | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05976997 | Duvelisib | Phase 2 | Newly Diagnosed Peripheral T-cell Lymphoma | Oncology | Dec 2026 |
| NCT02158091 | Duvelisib | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Dec 2026 |
| NCT04803201 | Duvelisib | Phase 2 | Angioimmunoblastic T-cell Lymphoma | Oncology | May 2027 |
| NCT05010005 | Duvelisib | Phase 1 | T-cell Lymphomas | Oncology | Aug 2027 |
| NCT03961672 | Duvelisib | Phase 2 | Recurrent Chronic Lymphocytic Leukemia | Oncology | Oct 2027 |
| NCT06522737 | Duvelisib | Phase 3 | Lymphoma | Oncology | Feb 2028 |
| NCT04652960 | Duvelisib | Phase 1 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Oncology | Jun 2028 |
| NCT06530550 | Duvelisib | Phase 2 | Lymphoma, T-Cell | Oncology | Jul 2028 |
| NCT05675813 | Duvelisib | Phase 1 | Peripheral T Cell Lymphoma | Oncology | Jul 2028 |
| NCT07293403 | Duvelisib | Phase 2 | Follicular Helper T-Cell Lymphoma | Oncology | Sep 2028 |
| NCT05044039 | Duvelisib | Phase 1 | Non-Hodgkin Lymphoma | Oncology | May 2030 |
| NCT06810778 | Duvelisib | Phase 1 | T-cell-prolymphocytic Leukemia | Oncology | Jun 2030 |
| NCT07001384 | Duvelisib | Phase 1 | Anaplastic Lymphoma Kinase | Oncology | Aug 2031 |
Rhizen Pharmaceuticals Incyte Biosciences Japan GK Pharming Technologies Incyte Kyowa Kirin Restorbio Celcuity Eli Lilly Sovargen Stelexis BioSciences
Rhizen Pharmaceuticals Verity Pharmaceuticals Fidia Farmaceutici Sumitomo Pharma Switzerland Eleison Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.